Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial

Journal of Gastrointestinal Surgery

Volumn 16, Issue 8, 2012, Pages 1531-1538

  Martin II, Robert C G ^a,b   Scoggins, Charles R ^a,b   Tomalty, Dana ^c   Schreeder, Marshall ^d   Metzger, Tiffany ^a   Tatum, Clifton ^e   Sharma, Vivek ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^c HUNTSVILLE HOSPITAL   (United States)

^d Clearview Cancer Institute   (United States)

^e Norton Radiology Associates   (United States)

Author keywords

Hepatic arterial therapy; Irinotecan; Liver directed therapy; Liver dominant metastatic colorectal cancer; Metastatic colon cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

AGED; ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG DELIVERY SYSTEM; FEMALE; FOLLOW UP; HUMAN; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84864081725     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1892-8     Document Type: Article

References (25)

1. Welch JP, Donaldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979; 189: 496-502.
2. Silverberg E. Cancer statistics, 1977. CA Cancer J Clin 1977; 27: 26-41.
3. Scheele J, Stangl R, Altendorf-Hofmann A et al. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991; 110: 13-29.
4. Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347-353.
5. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998; 25: 40-46.
6. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
7. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
8. Cheeseman SL, Joel SP, Chester JD et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002; 87: 393-399.
9. Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.
10. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
11. Martin RC, Joshi J, Robbins K et al. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol 2009; 2009: 539795.
12. Martin RC, Robbins K, Tomalty D et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009; 7: 80.
13. Martin RC, Joshi J, Robbins K et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011; 18: 192-198.
14. Bower M, Metzger T, Robbins K et al. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford) 2010; 12: 31-36.
15. Brown RE, Bower MR, Metzger TL et al. Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe? HPB (Oxford) 2011; 13: 91-95.
16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 2009; 45: 228-247.
17. Vauthey JN, Choti MA, Helton WS. AHPBA/SSO/SSAT consensus conference on hepatic colorectal metastases: rationale and overview of the conference. January 25, 2006. Ann Surg Oncol 2006; 13: 1259-1260.
18. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
19. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319.
20. Hebbar M, Tournigand C, Lledo G et al. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Cancer Invest 2006; 24: 154-159.
21. Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis group in cancer. Lancet 2000; 356: 373-378.
22. Martin RC, Howard J, Tomalty D et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010; 33: 960-966.
23. de Jonge MJ, Verweij J, de BP et al. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol 2000; 18: 195-203.
24. van Riel JM, van Groeningen CJ, Kedde MA et al. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002; 8: 405-412.
25. Mambrini A, Di Paolo A, Pacetti P, Muttini MP, Orlandi M, Danesi R, Fiorentini G, Cantore M. Pharmacokinetics of irinotecan: comparison of intravenous and intraarterial administration in patients with liver metastases. J Clin Oncol 2008; 26: 2234.